Clinical trials
Completed Anemia, Hemolytic trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
29 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 1 |
| 2009 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 2 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 29 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 4 |
| Agios Pharmaceuticals, Inc. | 3 |
| AO GENERIUM | 2 |
| Chengdu Suncadia Medicine Co., Ltd. | 2 |
| Hillhurst Biopharmaceuticals, Inc. | 2 |
| Alpine Immune Sciences Inc, A Subsidiary of Vertex | 1 |
| Boston Children's Hospital | 1 |
| Children's Hospital of Philadelphia | 1 |
| Copenhagen University Hospital at Herlev | 1 |
| Dartmouth-Hitchcock Medical Center | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Anemia, Hemolytic | 29 |
| Anemia | 8 |
| Anemia, Sickle Cell | 7 |
| Hematologic Diseases | 7 |
| Hemolysis | 7 |
| Fibrosis | 4 |
| Hepatitis C | 4 |
| Hepatitis C, Chronic | 4 |
| Anemia, Hemolytic, Autoimmune | 3 |
| Genetic Diseases, Inborn | 3 |
Trials
Showing 1 to 25 of 29. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.